

FIGURE 1




Figure 2




Figure 3




Figure 4A




Figure 4B




Figure 5A




Figure 5B




Figure 5C




Figure 5D






Figure 5E




Figure 5F




Figure 6A




Figure 6B




Figure 7A




Figure 7B




Figure 8A




Figure 8B






Fig. 9




Figure 10A




Figure 10B




Figure 10C




Figure 10D




Figure 11





Figure 12

1st dimension: Isoelectric focusing



2nd dimension: SDS PAGE




Figure 13






FIG. 14





FIG. 15






FIG. 16




Figure 17




Fig. 18




FIG. 19




FIG. 20




FIG. 21







FIG. 22



Sample	Protein	Area	Intensity
Disease	Int std	1139.044	3.340518
	marker	695.4804	0.580081
Drug treated	Int std	1383.883	3.780178
	marker	71.05119	0.143227

Fig. 22D

Normalized marker peak area (marker/internal std):

Control	0.0
Disease	0.61
Drug treated	0.05

FIG. 23

# Retentate Map<sup>TM</sup> of Human Urine SELDI ProteinChip<sup>TM</sup> Array




FIG. 24




FIG. 25





FIG. 26




Fig. 26A

Fig. 26B

Fig. 26C

Fig. 26D

FIG. 27

TGF $\beta$  (1  $\mu$ g/ml 2.5xconditioned medium)




Fig. 27A

Binding in the absence of free receptor (—)

Binding in the presence of excess free receptor (---)

TGF $\beta$  (100 ng/ml 2.5xconditioned medium)




Fig. 27B

FIG. 28




Figure 30






Figure 31




FIG. 33

Fig. 33A

Intensity

Fig. 33B

